Advanced glycation and endothelial functions: A link towards vascular complications in diabetes

被引:109
作者
Rojas, A [1 ]
Morales, MA [1 ]
机构
[1] Univ Chile, Fac Med, Programa Farmacol Mol & Clin, ICBM,Lab Farmacodinamia & Fitofarmacol, Santiago 7, Chile
关键词
advanced glycation; diabetes; endothelium; vascular complications;
D O I
10.1016/j.lfs.2004.09.011
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The formation of advanced glycation end-products (AGEs), also called the Maillard reaction. occurs ubiquitously and irreversibly in patients with diabetes mellitus, and its consequences are especially relevant to vascular dysfunctions. The interaction of AGEs with their receptors (RAGE) has been implicated in the development of vascular complications. This interaction elicits remarkable vascular cell changes analogous to those observed in diabetes mellitus, including angiogenic and thrombogenic responses of endothelial cells increased oxidative stress, and functional alterations in vascular tone control. This review focuses on AGEs formation, the interaction with their specific receptors and how the triggered intracellular events determine functional alterations of vascular endothelium. Finally, some potential pharmacological approaches undertaken to circumvent the deleterious effects of AGEs are also discussed. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:715 / 730
页数:16
相关论文
共 120 条
[51]   Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products:: Biochemical mechanisms [J].
Miyata, T ;
De Strihou, CV ;
Ueda, Y ;
Ichimori, K ;
Inagi, R ;
Onogi, H ;
Ishikawa, N ;
Nangaku, M ;
Kurokawa, K .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10) :2478-2487
[52]   NON-ENZYMATIC BROWNING INVIVO - POSSIBLE PROCESS FOR AGING OF LONG-LIVED PROTEINS [J].
MONNIER, VM ;
CERAMI, A .
SCIENCE, 1981, 211 (4481) :491-493
[53]   The double life of HMGB1 chromatin protein:: architectural factor and extracellular signal [J].
Müller, S ;
Scaffidi, P ;
Degryse, B ;
Bonaldi, T ;
Ronfani, L ;
Agresti, A ;
Beltrame, M ;
Bianchi, ME .
EMBO JOURNAL, 2001, 20 (16) :4337-4340
[54]   Therapeutic usefulness of Keishi-bukuryo-gan for diabetic nephropathy [J].
Nakagawa, T ;
Yokozawa, T ;
Terasawa, K ;
Nakanishi, K .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (02) :219-227
[55]  
Nakamura N, 2003, IN VIVO, V17, P177
[56]  
Nakayama M, 1999, PERITON DIALYSIS INT, V19, P207
[57]   Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model [J].
Nangaku, M ;
Miyata, T ;
Sada, T ;
Mizuno, M ;
Inagi, R ;
Ueda, Y ;
Ishikawa, N ;
Yuzawa, H ;
Koike, H ;
De Strihou, CV ;
Kurokawa, K .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (05) :1212-1222
[58]   MONOCYTE ADHESION AND TRANSMIGRATION IN ATHEROSCLEROSIS [J].
NAVAB, M ;
HAMA, SY ;
NGUYEN, TB ;
FOGELMAN, AM .
CORONARY ARTERY DISEASE, 1994, 5 (03) :198-204
[59]  
NEEPER M, 1992, J BIOL CHEM, V267, P14998
[60]   Biological effects of aminoguanidine: An update [J].
Nilsson, BO .
INFLAMMATION RESEARCH, 1999, 48 (10) :509-515